OTCM
MVIBF
Market cap44mUSD
, Last price
USD
Name
Mevis Medical Solutions AG
Chart & performance
P/E
—
P/S
—
EPS
1.74
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
-1.28%
Div Yld LY
—
Div Yld TTM
—
Revenues
16m
-5.37%
Net income
3m
-30.58%
CFO
4m
+23.29%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MeVis Medical Solutions AG develops software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company provides image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological diseases. It also offers X-ray based radiography procedures, including computed tomography, mammography/digital tomosynthesis, magnetic resonance imaging, and digital sonography; as well as provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. In addition, the company provides three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians; and internet-based special applications in teleradiology. The company was founded in 1997 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Corporation.
Key people
Marcus Kirchhoff
Chairman of the Executive Board, Chief Executive Officer · since 2012
Deputy Chairman of the Supervisory Board · since 2021
Kimberley Honeysett
Chairman of the Supervisory Board · since 2017
Sunny Sanyal
Member of the Supervisory Board · since 2021
Headquarters & legal address
Caroline-Herschel-Straße 1
Bremen, HB 28359
DE
Bremen, HB 28359
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||